138 related articles for article (PubMed ID: 38181739)
21. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.
Luo H; Wang W; Mai J; Yin R; Cai X; Li Q
Front Immunol; 2023; 14():1267918. PubMed ID: 37881432
[TBL] [Abstract][Full Text] [Related]
22. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Loo K; Smithy JW; Postow MA; Betof Warner A
Front Immunol; 2021; 12():810388. PubMed ID: 35087529
[TBL] [Abstract][Full Text] [Related]
23. Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy.
Vanmeerbeek I; Borras DM; Sprooten J; Bechter O; Tejpar S; Garg AD
Genes Immun; 2021 Jun; 22(2):108-119. PubMed ID: 34079092
[TBL] [Abstract][Full Text] [Related]
24. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.
Lim SY; Shklovskaya E; Lee JH; Pedersen B; Stewart A; Ming Z; Irvine M; Shivalingam B; Saw RPM; Menzies AM; Carlino MS; Scolyer RA; Long GV; Rizos H
Nat Commun; 2023 Mar; 14(1):1516. PubMed ID: 36934113
[TBL] [Abstract][Full Text] [Related]
25. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
[TBL] [Abstract][Full Text] [Related]
26. hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P; Tocci A; Palermo B; Di Carlo A; D'Ambrosio L; D'Andrea D; Di Modugno F; De Nicola F; Goeman F; Corleone G; Warren S; Paolini F; Panetta M; Sperduti I; Baldari S; Visca P; Carpano S; Cappuzzo F; Russo V; Tripodo C; Zucali P; Gregorc V; Marchesi F; Nistico P
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37612043
[TBL] [Abstract][Full Text] [Related]
27. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Boshuizen J; Pencheva N; Krijgsman O; Altimari DD; Castro PG; de Bruijn B; Ligtenberg MA; Gresnigt-Van den Heuvel E; Vredevoogd DW; Song JY; Visser N; Apriamashvili G; Janmaat ML; Plantinga TS; Franken P; Houtkamp M; Lingnau A; Jure-Kunkel M; Peeper DS
Cancer Res; 2021 Apr; 81(7):1775-1787. PubMed ID: 33531370
[TBL] [Abstract][Full Text] [Related]
28. Deactivation of ligand-receptor interactions enhancing lymphocyte infiltration drives melanoma resistance to Immune Checkpoint Blockade.
Sahni S; Wang B; Wu D; Dhruba SR; Nagy M; Patkar S; Ferreira I; Wang K; Ruppin E
bioRxiv; 2023 Sep; ():. PubMed ID: 37886558
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma.
Chakraborty B; Byemerwa J; Shepherd J; Haines CN; Baldi R; Gong W; Liu W; Mukherjee D; Artham S; Lim F; Bae Y; Brueckner O; Tavares K; Wardell SE; Hanks BA; Perou CM; Chang CY; McDonnell DP
J Clin Invest; 2021 Dec; 131(23):. PubMed ID: 34637400
[TBL] [Abstract][Full Text] [Related]
30. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
Auslander N; Zhang G; Lee JS; Frederick DT; Miao B; Moll T; Tian T; Wei Z; Madan S; Sullivan RJ; Boland G; Flaherty K; Herlyn M; Ruppin E
Nat Med; 2018 Oct; 24(10):1545-1549. PubMed ID: 30127394
[TBL] [Abstract][Full Text] [Related]
31. High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy.
Quek C; Bai X; Long GV; Scolyer RA; Wilmott JS
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34681023
[TBL] [Abstract][Full Text] [Related]
32. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
33. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of Drug Resistance in Melanoma.
Winder M; Virós A
Handb Exp Pharmacol; 2018; 249():91-108. PubMed ID: 28275910
[TBL] [Abstract][Full Text] [Related]
35. M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance.
Zheng N; Wang T; Luo Q; Liu Y; Yang J; Zhou Y; Xie G; Ma Y; Yuan X; Shen L
Oncoimmunology; 2023; 12(1):2210959. PubMed ID: 37197441
[TBL] [Abstract][Full Text] [Related]
36. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
37. Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.
Xia F; Yu Z; Deng A; Gao G
Exp Biol Med (Maywood); 2022 Feb; 247(3):246-262. PubMed ID: 34743576
[TBL] [Abstract][Full Text] [Related]
38. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
39. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]